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Abstract: Panic is an often incapacitating and
chronic disorder. Cognitive behaviour therapy
(CBT) and alprazolam have been shown to be
effective in the treatment of panic disorder.
Patients who met the DSM-III-R criteria for
panic disorder, were randomized and given
16 weeks of double-blind treatment with
CBT (n=16), or alprazolam of up to 6
mg/day (n=18). The 17-item HAM-D and
HAM-A scales were administered to all the
subjects before and after treatment, which
took place over 16 weeks, and the changes in
the scores were analyzed. The patients’
anxiety levels and numbers of panic attacks
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Introduction
Panic disorder is a common anxiety disorder
associated with a great deal of distress as well as marked
social and occupational disability (1,2). Such patients are
over-represented with regard to the use of medical
services, such as emergency room visits, the number of
visits to physicians and the use of psychotropic
medications (3,4,5,). In addition, their rate of attempted
suicide has been reported to be either greater to that of
the general population or equal to that of patients
suffering from major depression (6,7,8).
Clinical evidence suggests that cognitive-behaviour
therapy (CBT) is an effective treatment for panic. For
example, Gitlin et al. reported that 10 out of 11 patients
receiving CBT were not panicking by the end of treatment
(9). Beck, Ost, Craske have also reported nearly total
elimination of panic in patients suffering from panic
disorder using either cognitive behavioral or behaviorallybased relaxation treatments (10,11,12).
In the 1980s, a new class of benzodiazepines, the
triazolobenzodiazepines, became available. One member
of that class, alprazolam, has been reported to be
effective in the treatment of panic disorder (13,14).

were assessed at the beginning of treatment,
and then at weeks 4,8,12 and 16 by means
of self-monitoring. On the basis of HAM-D,
HAM-A, anxiety level, and panic number, the
CBT and alprazolam groups showed a
significant improvement at the end of
treatment. When compared to each other, the
groups showed no significant differences at
the end of the treatment. In the last month,
10/16 (62.5%) of the CBT patients and
11/18 (61.1%) of the alprazolam patients
were panic-free.
Key Words: Alprazolam, Cognitive behavior
therapy, Panic disorder.

To our knowledge, few reports have compared the
efficiency of both treatment in patients with panic
disorder. In view of the effectiveness of this CBT and of
alprazolam in panic disorder, the purpose of this study
was to evaluate the effectiveness of each treatment.
Materials and Method
Subjects: Patients were drawn from patients
attending the psychiatry clinic. All had been given a
diagnosis of panic disorder with mild or no agoraphobic
avoidance, using DSM-III-R criteria. Only patients with at
least four panic attacks within a four-week period, or
those experiencing one or more attacks followed by a
period of at least a month of persistent fear of another
attack were included.
The general exclusion criteria were as follows: age
below 18 or above 65 years, current drug or alcohol
abuse/dependency, principal diagnosis of major
depression, and any signs of psychosis or organic brain
syndrome. Finally, subjects were excluded if they had
begun taking benzodiazepines or antidepressants within
the previous six months.
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At the onset of treatment, the subjects comprised 40
patients with panic disorder.
The patients were treated with either CBT or
alprazolam for two months, and then followed for two
months without CBT and alprazolam.
Measures: Clinical assessment measures consisting of
the Hamilton Anxiety Rating Scale (HAM-A) and the
Hamilton Rating Scale for Depression (HAM-D) were
administered to all subjects before and after treatment,
and the changes in the scores were analyzed.
A self-monitoring measure was administered at the
beginning of treatment and assessed at 4-week periods
throughout treatment. Patients monitored their current
levels of anxiety on a 0-to-8-point visual analogue scale,
four times a day (morning, afternoon, evening and
bedtime), stating whether or not they experienced panic
(patients were instructed and trained to define and
differentiate a panic attack from episodes of generalized
anxiety). The data from the visual analogue scale served
to measure the anxiety level and panic number
Alprazolam treatment group: Patients received
1mg doses of alprazolam (1 or 2 mg) up to four times
daily. Medication was gradually increased until the
maximum benefit was achieved or dose-limiting side
effects occurred. Patients began taking one tablet per day
(for two days) and then this was increased to two tablets
(for three days), three tablets (for four days), four tablets
(for four days), five tablets (for four days), and then six
tablets per day on day 18. When side effects were
reported, these increases in medication were slowed or
the dose was reduced. Every effort was made to achieve
a dosage of six tablets per day.
Patients were given an explanation of their condition,
including what could be expected of the medication. No
other centrally active medications were administered
during the trial.
At the beginning of the 9th week of treatment, the
psychiatrist began to taper the doses of alprazolam at a
rate no faster than one tablet every 3 days. The
psychiatrist continued meeting patients until they had
stopped taking medication completely.
CBT group: The treatment consisted of a 2-month
course of CBT. The patients received 8 individual sessions
of CBT for panic disorder in weekly meetings. Exposure
plus cognitive restructuring were applied in the case of
these patients. Treatment comprised a rationale and
education concerning panic disorder, the components of
anxiety and emphasized exposure to somatic cues.
Cognitive approaches were also included. In cognitive
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therapy, we helped the patients to identify and modify
their negative thoughts. In addition, the patients were
encouraged to expose themselves to situations or
activities which they were avoiding. They were also
encouraged to modify behaviours which occur once
symptoms have started and which maintain a patient’s
belief that certain symptoms are highly dangerous.
Results
Out of 40 initial patients, 34 patients completed the
study, and 6 patients dropped out. A higher rate of drop
out was observed in the CBT group than in the other
group. Two patients out of 20 (10%) dropped out of the
alprazolam group, while 4 out of 20 (20%) dropped out
of the CBT group.
A t-test analysis on these dorp-out frequencies
showed no significant differences between the CBT and
alprazolam group (t=1.03,p=0.314).
Patients who dropped out of the study were
questioned about their reasons. Of the 4 patients who
dropped out of the CBT group, 2 developed intense panic
attacks in the 1st week of the treatment, causing them to
drop out of the study. Two were unavailable for interview
after the second week of treatment. The 2 subjects who
dropped out of the alprazolam treatment group stated
that they disliked the side effects of the medication in the
1 st week of treatment (1 reported over-sedation, and 1
reported suicidal ideation).
In the CBT group, 9 men (56%) and 7 women (43%)
completed the study. The mean age was 30.81 years. In
the alprazolam group, 6 men (44%) and 12 women
(56%) completed the study. The mean age was 31.44
years. The mean age difference between the groups was
not significant (F=0.574, df=32, t=-0.234, p>0.05).
In the CBT group (16 patients), the mean score on the
Hamilton Depression Scale at week 0 was 12.06 (range,
2 to 45), with only 5 patients (31.2%) scoring values
above 14. In the alprazolam group (18 patients), the
mean score on the Hamilton Depression Scale at week 0
was 10.83 (range, 2 to 40), with only 6 patients
(33.3%) scoring in the range above 14.
In the study intake, no statistical difference between
the two groups in the average HAM-D and HAM-A scores
were found using the Mann-Whitney test (z=-0.657,
p>0.528), (z=-0.346, p>0.746).
In terms of HAM-D scores, the CBT and alprazolam
groups showed a statistically significant improvement on
the Wilcoxon signed rank test at the end of the 4 months,
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and there was no difference between the groups on the
Mann-Whitney test (Table 1).
The scores on HAM-A were found to have decreased
significantly at the end of the treatment in the cognitivebehavior and alprazolam groups on the Wilcoxon signed
rank test. This is described in Table 1. The differences in
anxiety scores in both groups found at the end of the
study were compared, but the decrease in anxiety scores
was not found to be significant on the Mann-Whitney
test. This is described in Table 1.
In the CBT group, anxiety level (on the 0-8 scale)
from baseline to end point was compared using the
Friedman test and the decrease in anxiety level was found
to be significant (x2=50.888, df=4, p<0.0001). Similarly,
in the alprazolam group the decrease in anxiety level was
found to be significant on the Friedman test (x2=30.499,
df=4, p<0.0001).
Table 1.

after treat.
anxiety score
Mean
SD

Cog.

31.18

4.13

20.37

7.57

Alp.

31.77

4.79

23.27

5.86

z=-1.491,

Cog. treatment group
Mean
SD
12.06
18.81
6.43
3.00
0.68

5.91
8.43
4.64
4.13
0.94

Cog. treatment group
Mean
SD
Baselinea
1-Month
2-Month
3-Month
4-Month

Both CBT and alprazolam significantly reduced panic
frequency at the end of the treatment according to the
results of the Friedman test (x2=26.160, df=4,
p<0.0001), (x2=16.987, df=4, p<0.002). In the endpoint analysis, 11/18 (61.1%) of the alprazolam patients
and 10/16 (62.5%) of the CBT patients had no panic
attacks in the last month. The number of panic attacks
did not show any statistically significant differences
between the two groups throughout the study (except in
the first month) on the Friedman test This is described in
Table 3.

The difference in anxiety and depression scores in both groups.

Before treat.
anxiety score
Mean
SD

Baseline
1-Month
2-Month
3-Month
4-Month

When the treatments were compared in terms of
anxiety level, it was found that most improvement
occurred with alprazolam in the first month, and then
with CBT in the third and fourth months. This is
described in Table 2.

93
1.37
18
31
12

68
1.08
40
60
34

Before treat.
depression score
Mean
SD
z=-3.239
P<0.001
z=-3.030
P<0.02
p>0.144

12.06

6.54

8.43

2.98

10.83

6.13

8.66

3.36

z=-0.208,

Alp. treatment group
Mean
SD
11.88
5.38
9.00
5.33
1.94

4.02
3.83
4.10
3.32
1.79

z=-0.104,
z=-4.199,
z=-1.800,
z=-2.501,
z=-2.320,

72
42
61
46
38

z=-2.332
p<0.02
z=-2.078
p<0.04
p>0.851

Table 2.

Anxiety levels reported
by each group.

Table 3.

Number
attacks.

p>0.932
p<0.001
p>0.075
p<0.01
p<0.025

Alp. treatment group
Mean
SD
94
22
44
27
16

After treat.
depression score
Mean
SD

of

panic

z=-0.19, p>0.97
z=-3.405,p<0.001
z=-1.326,p>0.3
z=-0. 067,p>0.96
z=-0.337,p>0.851
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Discussion
When a person is anxious, there are three different
components to his/her reaction: a physiological
component (e.g., increased heart rate, sweating, muscle
tension), a behavioural component (e.g. avoidance,
attempts to escape), and a cognitive component (negative
thoughts, such as “I am going to collapse”, “I cannot
cope”). The relative strength of these components varies
from person to person, but it is common for people to
experience a physiological change, followed by a negative
thought, which increases the physiological reaction,
producing a vicious circle. To break this vicious circle we
encouraged the patients to focus on and to expose
themselves to the physiological reaction which they were
avoiding. It was also important to modify behaviours
which occur once symptoms have started and which
maintain the patients’ belief that certain symptoms are
highly dangerous.
Cognitive-behavioral approaches are thought to have
an impact on panic and anxiety by affecting cognitive
rather than somatic symptoms. In this study, however, we
saw that patients’ somatic sensations were reduced and
we considered that this was related to cognitive change
concerning the disease in the patients. The cognitive
model of panic states that individuals experience panic
attacks because they have a relatively enduring tendency
to interpret a range of bodily sensations in a catastrophic
fashion. Sensations which are misinterpreted are mainly
those which can be involved in normal anxiety responses
(e.g. palpitation, breathlessness, dizziness). The
catastrophic misinterpretation involves perceiving these
sensations as indicative of an immediately impending
physical or mental disaster. For example, a patient who
was preoccupied with the idea he may be suffering from
cardiac disease avoided exercise whenever he noticed
palpitations. He believed that this avoidance helped to
prevent him from having a heart attack. However, as he

had no signs of cardiac disease, the real effect of the
avoidance was to prevent him from learning that the
symptoms he was experiencing were innocuous.
In this study, as the patients were prevented from
avoiding such situations, their negative thoughts about
body sensations changed, and these changed body
sensations changed their cognition of the disease.
Panic attacks were eliminated in a very large
percentage of patients (in the CBT group, 62.5%; in the
alprazolam group, 61.1%). These findings are similar to
reports of long-term clinical outcome studies testing CBT
for panic disorder in which nearly 70% of patients were
found to be panic-free (12, 15). These findings indicate
that CBT is an effective short-term treatment of panic
disorder. Studies comparing the long-term treatment and
short-term treatment of CBT in patients who have panic
disorder are needed to facilitate decision-making with
relation to therapy.
At the end of study, improvement in the anxiety and
depression scores of the two groups were observed. In
the number of panic attacks and in the anxiety level
significant differences favoring alprazolam over CBT were
observed in the first month of the study. In the patients’
reported anxiety levels, significant differences favoring
CBT over alprazolam were observed in the third and
fourth months. It is important to emphasize that
significant improvements observed clinically in the first
month in the alprazolam group were probably due to the
action of the alprazolam. This observation is consistent
with a slower onset of effects with CBT than with
alprazolam (16 ).
These findings, suggest that it might be beneficial to
start patients on alprazolam with a therapeutic contract
in order to withdraw them from alprazolam as CBT
progresses. In this way, patients are protected from the
long-term therapy risk of alprazolam.
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